THOMAS PICCARIELLO, PHD.
CO-FOUNDER, PRESIDENT AND CHIEF SCIENCE OFFICER
Prior to founding Synthonics, Dr. Piccariello was the lead inventor of New River Pharmaceuticals’ Carrierwave technology (attaching a peptide to an active agent to make that agent less subject to abuse), which New River incorporated into Vyvanse. Shortly after the launch of Vyvanse, Shire acquired New River for approximately $2.4 billion. Dr. Piccariello has experience in the fields of synthetic chemistry, metallurgy, electrochemistry, plant enzymology, chemical manufacturing and pharmacology. In addition to serving as the lead scientist for two pharmaceutical start-up companies (both of which became public), Dr. Piccariello founded and ran contract research and contract manufacturing companies, which he later sold. Dr. Piccariello has 23 patents and patent applications to his credit, 18 of which deal with novel drug delivery technologies. He has a B.S. in biology and a Ph.D. in chemistry from Virginia Polytechnic Institute and State University (Virginia Tech).
CEO AND CO-FOUNDER
Mr. Tinkham has spent much of his career as a transactional lawyer focusing on technology licensing, public and private mergers and acquisitions and corporate finance. After practicing with Latham & Watkins and Skadden Arps in San Francisco and Seattle, he served as assistant general counsel at Integra Lifesciences, where he led their mergers and acquisitions and licensing practices. He studied economics at Northwestern University and law at the University of California, Berkeley School of Law, where he was the editor-in-chief of the California Law Review.
VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
Dr. Price has over 20 years of discovery and development experience in the pharmaceutical and biotechnology industries. He holds several patents relating to metal coordination chemistry. He has a B.S. in chemical engineering from Washington University and a Ph.D. in organic chemistry from Iowa State University.